Domestic drug makers Sun Pharma and Alembic are recalling products in the US market due to manufacturing issues, according to the US Food and Drug Administration (USFDA).
As per the US health regulator’s latest Enforcement Report, the Mumbai-based drug major is recalling 12,336 bottles of Buprenorphine Sublingual tablets, used for treating opioid use disorder, in the American market.
Sun Pharmaceutical Industries Inc, the US-based arm of the company, is recalling the affected lot (8 mg, 30 count-bottles) due to CGMP (Current Good Manufacturing Practice) deviations, the USFDA stated. The company initiated the Class II voluntary recall on May 3 this year.
Sun Pharma is also recalling 7,313 bottles of Methylphenidate Hydrochloride tablets, used to treat attention deficit hyperactivity disorder, in the US market.
New Jersey-based Sun Pharmaceutical Industries Inc is recalling the lot due to the “presence of foreign substance: metal embedded in a tablet”, the USFDA stated. The company initiated the recall on July 13 this year, it added.
If you or a loved one suffered losses due to ingesting this, or any, defective drug, you may be entitled to compensation. To learn more, contact the trusted product liability attorneys at Breslin and Breslin today.
